Longeveron Inc. to Share Innovations at Upcoming Conference
MIAMI, Longeveron Inc. (NASDAQ: LGVN), a pioneering biotechnology firm, is gearing up to present at the 37th Annual Roth Conference. This prominent event will take place on March 17-18, focusing on advancements in regenerative medicine. Longeveron specializes in developing cellular therapies aimed at treating chronic aging-related conditions.
Details of the Conference Presentation
As part of their participation, Longeveron will engage in a fireside chat on Tuesday, March 18. This presentation aims to enlighten attendees about the company's innovative therapeutic approaches, particularly their lead product, Lomecel-B™.
Important Presentation Details
The schedule for Longeveron’s fireside chat is as follows:
- Date: March 18
- Time: 9:00 – 9:25 a.m. PT
Accessing the Webcast
Those interested in Longeveron's presentation can access the webcast through the "Events and Presentations" section on their official website. A replay of the presentation will be available for 90 days post-event, ensuring that interested parties can view the insights shared.
About Longeveron Inc.
Longeveron Inc. is at the forefront of regenerative medicine, focusing on unmet medical needs and offering promising solutions through their cellular therapies. Their flagship product, Lomecel-B™, is derived from the bone marrow of healthy adults, comprising allogeneic medicinal signaling cells. This therapy is under investigation for treating various conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer's disease.
Pipeline and Regulatory Recognition
The company's strategic pipeline includes conditions like Aging-related Frailty, positioning Lomecel-B™ as a versatile therapeutic option. This program has gained significant traction, receiving several important FDA designations, including Orphan Drug and Fast Track designations for HLHS, as well as RMAT designation for Alzheimer's treatment.
Company Contact Information
For additional information or inquiries, interested parties can contact:
Derek Cole
Investor Relations Advisory Solutions
Email: derek.cole@iradvisory.com
Frequently Asked Questions
What is Longeveron Inc. known for?
Longeveron Inc. is recognized for developing regenerative medicines to address various health challenges, particularly in aging-related diseases.
When is Longeveron's presentation at the Roth Conference?
The presentation is scheduled for March 18, with a time slot from 9:00 to 9:25 a.m. PT.
How can I watch Longeveron's conference presentation?
The webcast can be accessed from the "Events and Presentations" section of Longeveron's website and will be available for replays for 90 days following the event.
What is Lomecel-B™?
Lomecel-B™ is an innovative therapy derived from healthy adult donors, developed to improve outcomes in various medical conditions.
Who should I contact for more information about Longeveron?
You can reach out to Derek Cole via email at derek.cole@iradvisory.com for investor-related inquiries.